Menu
Washingtoner
  • Home
  • Artificial Intelligence
  • Health
  • Technology
  • Entertainment
  • Real Estate
  • Software
  • Business
  • Education
Washingtoner

Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
Washingtoner/10239600

Trending...
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
A rigorous three-month longitudinal cohort study of several of flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

BOISE, Idaho - Washingtoner -- Lotus Vaping Technologies, LLC, a Boise, Idaho-based manufacturer of bottled e-liquids for use in electronic nicotine delivery systems ("ENDS") or e-cigarettes, announced today that a rigorous three-month longitudinal cohort study of several of its FreenomsTM branded flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

The three-month study conducted from March 2023 to August 2023 involved 451 randomly assigned participants who were cigarette smokers, 221 of which were assigned to a control group that used only tobacco-flavored e-liquid, and 230 of which were assigned to a group that could use any of five different non-tobacco flavored bottled e-liquids, including Lotus's proprietary BluenomenomTM, StranomenonTM, X2 Cactus Jackfruit, and White Peach Raspberry flavors.

More on Washingtoner
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Spokane City Council Passes Chronic Nuisance Properties Ordinance
  • City of Spokane and City Council Announce 2027 Legislative Priorities
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services

At the end of three months, the average number of cigarettes smoked per day ("CPD") by the tobacco-flavored control group was reduced from 12.51 to 9.54, for a 23.72% reduction, while for the flavored e-liquid group, the average CPD was reduced from 11.70 to 6.88, for a 41.25% reduction.  The reduction in cigarettes smoked per day was thus 73.9% greater for the flavored group than the tobacco-flavored group. The study results also demonstrated statistically significant differences between several of Lotus's flavored e-liquids when compared head-to-head against tobacco-flavored e-liquids with respect to CPD reduction.

Additionally, a full 14.3% of study participants in the flavored group had quit smoking cigarettes altogether by the end of the third month—a rate that is substantially higher than that typically reported for FDA-approved nicotine replacement therapy products (9.0%).

Lotus's Director of Sales, Mike Larsen stated, "We are very excited about these study results. This study demonstrates what users of our products have known anecdotally for a long time—flavored e-liquids are more effective than tobacco flavor at promoting cigarette smoking reduction and cessation. The FDA has been asking for this data—we hope it will now take it into consideration when reviewing our premarket tobacco product applications and grant our flavored products the marketing authorizations that they deserve."

More on Washingtoner
  • Tacoma: Council Member Sandesh Sadalge Focuses Today's District 4 Town Hall on the City's Biennial Budget
  • City of Tacoma Awarded $2.25 Million in Federal Highway Safety Improvement Program Grant Funding for South 21st Street Corridor
  • New Self-Service Sandbag Station at Tacoma Recovery and Transfer Center
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props

About Lotus Vaping Technologies, LLC – Creator of NomenonsTM E-Liquids

Established in 2013, Lotus is a leading manufacturer and wholesaler of premium e-liquids in the United States providing a diverse range of vapor products for sale to adult consumers that satisfy a wide variety of consumer preferences and serve as alternatives to combustible cigarettes. Lotus is committed to responsible manufacturing processes and utilizes only the highest standards in its e-liquid production.

Media Contact
Mike Larsen
mike@lotusecigs.com


Source: Lotus Vaping Technologies, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration
  • Andrew Balzano Releases One of My Life's Passions: Classics and Mysteries, a Fan's Guide to Great Mysteries Worth Rewatching
  • Spokane: City Details Veterans Day Schedule
  • The 4th Annual Newark Summit for Economic Development, Placemaking & Innovation Returns on December 8th
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • Washington Nurse Introduces Nightingale Care Hub to Help Families Organize Care
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Flags Lowered for Spokane County Sheriff Deputies
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
  • ARADIA (Est. 1991) Launches First B2A Partner Program for AI
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Spokane: Drugs and Guns Seized in a Counter Narcotics Investigation
  • Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Spokane: City and County Issue Joint Housing and Homelessness Funding RFP
  • Spokane: Council Approves Additional Funding to Prepare for Inclement Weather
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 278
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 245
  • Final Week to Register for Free Spokane Community Conference - 226
  • Author Robert A. Robinson Introduces Anarchy at the AYP: - 149
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 145
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 124
  • Sycamore Dove Releases "Loving Every Moment" - 102
  • FloorLine Launches Live Shop Floor Tracking for Small Manufacturers
  • One in three Americans may have lost track of retirement savings from a previous job
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026

Similar on Washingtoner

  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute